{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-17T06:29:36.561976+00:00","company":{"ticker":"PLYX","cik":2075320,"company_name":"Polaryx Therapeutics, Inc."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"approximately 35 investors, including existing investors","detail":"equity_purchase","count":1,"first_seen":"2026-05-28T20:31:45+00:00","last_seen":"2026-05-28T20:31:45+00:00","evidence_fact_ids":[84847]}]},"facts":[{"fact_type":"equity_issuance","fact_key":"ed8d3cd9c678e5dc0e68394753f97080a56bb27a","cik":2075320,"ticker":"PLYX","company_name":"Polaryx Therapeutics, Inc.","filed_at":"2026-05-28T20:31:45+00:00","payload":{"action":"private_placement","consideration_text":"aggregate gross proceeds of $10 million","effective_date":"2026-05-27","item_codes_triggered":["3.02"],"purchaser":"approximately 35 investors, including existing investors","security_type":"common_stock","shares_text":"2,502,696 shares"},"claim":"Polaryx Therapeutics, Inc. issued 2,502,696 shares of common stock to approximately 35 investors, including existing investors for aggregate gross proceeds of $10 million.","evidence_excerpt":"On May 27, 2026, Polaryx Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with approximately 35 investors, including existing investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement a total of 2,502,696 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Private Placement”), representing approximately 5.3% of the Company’s outstanding shares immediately prior to the Private Placement, for aggregate gross proceeds of $10 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-062155","anchor_url":"https://secwatch.observer/filing/0001213900-26-062155#claim-ed8d3cd9c678e5dc0e68394753f97080a56bb27a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2075320/000121390026062155/0001213900-26-062155-index.htm"},{"fact_type":"material_agreement","fact_key":"a2d99f54cc9f8c388bc9084ad329ecef49027ec7","cik":2075320,"ticker":"PLYX","company_name":"Polaryx Therapeutics, Inc.","filed_at":"2026-05-28T20:31:45+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"approximately 35 investors, including existing investors (the \"Purchasers\")","effective_date":"2026-05-27","item_codes_triggered":["1.01"],"value_text":"$10 million"},"claim":"Polaryx Therapeutics, Inc. entered into Securities Purchase Agreement with approximately 35 investors, including existing investors (the \"Purchasers\") valued at $10 million (effective 2026-05-27).","evidence_excerpt":"On May 27, 2026, Polaryx Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with approximately 35 investors, including existing investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement a total of 2,502,696 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Private Placement”), representing approximately 5.3% of the Company’s outstanding shares immediately prior to the Private Placement, for aggregate gross proceeds of $10 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-26-062155","anchor_url":"https://secwatch.observer/filing/0001213900-26-062155#claim-a2d99f54cc9f8c388bc9084ad329ecef49027ec7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2075320/000121390026062155/0001213900-26-062155-index.htm"}]}